Risk of disease relapse following rituximab for patients with glucocorticoid and without glucocorticoid maintenance therapy at last follow-up or relapse.

Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy

Mignard, Claire
Maho-Vaillant, Maud
Golinski, Marie-Laure
Balayé, Pierre
Prost-Squarcioni, Catherine
Houivet, Estelle
Calbo, Sé Bastien
Labeille, Bruno
Picard-Dahan, Catherine
Konstantinou, Maria Polina
Chaby, Guillaume
Richard, Marie-Aleth
Bouaziz, Jean-David
Duvert-Lehembre, Sophie
Delaporte, Emmanuel
Bernard, Philippe
Caux, Frédéric
Alexandre, Marina
Ingen-Housz-Oro, Saskia
Vabres, Pierre
Quéreux, Gaelle
Dupuy, Alain
Debarbieux, Sebastien
Avenel-Audran, Martine
d'Incan, Michel
Bedane, Christophe
Beneton, Nathalie
Jullien, Denis
Dupin, Nicolas
Misery, Laurent
Machet, Laurent
Beylot-Barry, Marie
Dereure, Olivier
Sassolas, Bruno
Bénichou, Jacques
Joly, Pascal
Hebert, Vivien
Calbo, Sébastien

May 2020

International audienceImportance: Rituximab and short-term corticosteroid therapy are the criterion ...

Rituximab for the Treatment of Relapses in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Miloslavsky, E. M.
Specks, U.
Merkel, P. A.
Seo, P.
Spiera, R.
Langford, C. A.
Hoffman, G. S.
Kallenberg, C. G. M.
Clair, E. W. St.
Tchao, N. K.
Viviano, L.
Ding, L.
Ikle, D.
Villarreal, M.
Jepson, B.
Brunetta, P.
Allen, N. B.
Fervenza, F. C.
Geetha, D.
Keogh, K.
Kissin, E. Y.
Monach, P. A.
Peikert, T.
Stegeman, C.
Ytterberg, S. R.
Stone, J. H.

November 2014

Objective. Disease relapses are frequent in anti-neutrophil cytoplasmic antibody-associated vasculit...

Rituximab Treatment for Relapsing Minimal Change Disease and Focal Segmental Glomerulosclerosis: A Systematic Review

Kronbichler, Andreas
Kerschbaum, Julia
Fernandez-Fresnedo, Gema
Hoxha, Elion
Kurschat, Christine E.
Busch, Martin
Bruchfeld, Annette
Mayer, Gert
Rudnicki, Michael

January 2014

Background: Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) remain a ther...

Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome

Ruggenenti P
Ruggiero B
Cravedi P
Vivarelli M
Massella L
Marasà M
Chianca A
Rubis N
Ene Iordache B
Rudnicki M
POLLASTRO, Rosa Maria
CAPASSO, Giovambattista
Pisani A
Pennesi M
Emma F
Remuzzi G.

January 2014

The outcome of steroid-dependent or frequently relapsing nephrotic syndrome of minimal change diseas...

Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease

Diankun Liu
Zhanmei Zhou
Mengyi Wang
Sheng Nie
Jun Li
Bianxiang Hu
Wenjuan He
Guobao Wang
Jun Ai

July 2021

Abstract Background Minimal change disease is a common cause of nephrotic syndrome in adults. Higher...

Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients.

D'Arena, G
Simeon, V
Laurenti, L
Cimminiello, M
Innocenti, I
Gilio, M
Padula, A
Vigliotti, Ml
De Lorenzo, S
Loseto, G
PASSARELLI, ANNA
Di Minno, Mn
TUCCI, MARCO GAETANO
De Feo, V
D'Auria, F
SILVESTRIS, Francesco
Di Minno, G

January 2017

Rituximab is an effective treatment for CD20þB-cell malignancies and autoimmune disorders.However, a...

Safety of rituximab for remission maintenance in relapsing anca–associated vasculitis: repeat cycles on clinical relapse are associated with low rates of hypogammaglobulinaemia.

Yusof, MYM
Vital, E
Dass, S
Pease, C
Martin, M
Savic, S
Buch, M
Emery, P

January 2013

Background: Rituximab is effective in ANCA-associated vasculitis (AAV). Since relapse often occurs a...

Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients

D\u2019Arena, Giovanni
Simeon, Vittorio
Laurenti, Luca (ORCID:0000-0002-8327-1396)
Cimminiello, Michele
Innocenti, Idanna
Gilio, Michele
Padula, Angela
Vigliotti, Maria Luigia
De Lorenzo, Sonya
Loseto, Giacomo
Passarelli, Anna
Di Minno, Matteo Nicola Dario
Tucci, Marco
De Feo, Vincenzo
D\u2019Auria, Fiorella
Silvestris, Francesco
Di Minno, Giovanni
Musto, Pellegrino

January 2017

Rituximab is an effective treatment for CD20 + B-cell malignancies and autoimmune disorders. However...

Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis

Alberici, Federico
Smith, Rona M.
Jones, Rachel B.
Roberts, Darren
Willcocks, Lisa C.
Chaudhry, Afzal
Smith, Kenneth GC
Jayne, David R.W.

June 2016

Objective. ANCA-associated vasculitis (AAV) is characterized by a chronic relapsing course. Rituxima...

Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy

Mignard, Claire
Maho-Vaillant, Maud
Golinski, Marie-Laure
Balayé, Pierre
Prost-Squarcioni, Catherine
Houivet, Estelle
Calbo, Sé Bastien
Labeille, Bruno
Picard-Dahan, Catherine
Konstantinou, Maria Polina
Chaby, Guillaume
Richard, Marie-Aleth
Bouaziz, Jean-David
Duvert-Lehembre, Sophie
Delaporte, Emmanuel
Bernard, Philippe
Caux, Frédéric
Alexandre, Marina
Ingen-Housz-Oro, Saskia
Vabres, Pierre
Quéreux, Gaelle
Dupuy, Alain
Debarbieux, Sebastien
Avenel-Audran, Martine
d'Incan, Michel
Bedane, Christophe
Beneton, Nathalie
Jullien, Denis
Dupin, Nicolas
Misery, Laurent
Machet, Laurent
Beylot-Barry, Marie
Dereure, Olivier
Sassolas, Bruno
Bénichou, Jacques
Joly, Pascal
Hebert, Vivien
Calbo, Sébastien

May 2020

International audienceImportance: Rituximab and short-term corticosteroid therapy are the criterion ...

Rituximab for the Treatment of Relapses in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Miloslavsky, E. M.
Specks, U.
Merkel, P. A.
Seo, P.
Spiera, R.
Langford, C. A.
Hoffman, G. S.
Kallenberg, C. G. M.
Clair, E. W. St.
Tchao, N. K.
Viviano, L.
Ding, L.
Ikle, D.
Villarreal, M.
Jepson, B.
Brunetta, P.
Allen, N. B.
Fervenza, F. C.
Geetha, D.
Keogh, K.
Kissin, E. Y.
Monach, P. A.
Peikert, T.
Stegeman, C.
Ytterberg, S. R.
Stone, J. H.

November 2014

Objective. Disease relapses are frequent in anti-neutrophil cytoplasmic antibody-associated vasculit...

Rituximab Treatment for Relapsing Minimal Change Disease and Focal Segmental Glomerulosclerosis: A Systematic Review

Kronbichler, Andreas
Kerschbaum, Julia
Fernandez-Fresnedo, Gema
Hoxha, Elion
Kurschat, Christine E.
Busch, Martin
Bruchfeld, Annette
Mayer, Gert
Rudnicki, Michael

January 2014

Background: Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) remain a ther...

Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome

Ruggenenti P
Ruggiero B
Cravedi P
Vivarelli M
Massella L
Marasà M
Chianca A
Rubis N
Ene Iordache B
Rudnicki M
POLLASTRO, Rosa Maria
CAPASSO, Giovambattista
Pisani A
Pennesi M
Emma F
Remuzzi G.

January 2014

The outcome of steroid-dependent or frequently relapsing nephrotic syndrome of minimal change diseas...

Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease

Diankun Liu
Zhanmei Zhou
Mengyi Wang
Sheng Nie
Jun Li
Bianxiang Hu
Wenjuan He
Guobao Wang
Jun Ai

July 2021

Abstract Background Minimal change disease is a common cause of nephrotic syndrome in adults. Higher...

Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients.

D'Arena, G
Simeon, V
Laurenti, L
Cimminiello, M
Innocenti, I
Gilio, M
Padula, A
Vigliotti, Ml
De Lorenzo, S
Loseto, G
PASSARELLI, ANNA
Di Minno, Mn
TUCCI, MARCO GAETANO
De Feo, V
D'Auria, F
SILVESTRIS, Francesco
Di Minno, G

January 2017

Rituximab is an effective treatment for CD20þB-cell malignancies and autoimmune disorders.However, a...

Safety of rituximab for remission maintenance in relapsing anca–associated vasculitis: repeat cycles on clinical relapse are associated with low rates of hypogammaglobulinaemia.

Yusof, MYM
Vital, E
Dass, S
Pease, C
Martin, M
Savic, S
Buch, M
Emery, P

January 2013

Background: Rituximab is effective in ANCA-associated vasculitis (AAV). Since relapse often occurs a...

Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients

D\u2019Arena, Giovanni
Simeon, Vittorio
Laurenti, Luca (ORCID:0000-0002-8327-1396)
Cimminiello, Michele
Innocenti, Idanna
Gilio, Michele
Padula, Angela
Vigliotti, Maria Luigia
De Lorenzo, Sonya
Loseto, Giacomo
Passarelli, Anna
Di Minno, Matteo Nicola Dario
Tucci, Marco
De Feo, Vincenzo
D\u2019Auria, Fiorella
Silvestris, Francesco
Di Minno, Giovanni
Musto, Pellegrino

January 2017

Rituximab is an effective treatment for CD20 + B-cell malignancies and autoimmune disorders. However...

Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis

Alberici, Federico
Smith, Rona M.
Jones, Rachel B.
Roberts, Darren
Willcocks, Lisa C.
Chaudhry, Afzal
Smith, Kenneth GC
Jayne, David R.W.

June 2016

Objective. ANCA-associated vasculitis (AAV) is characterized by a chronic relapsing course. Rituxima...

Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy

Mignard, Claire
Maho-Vaillant, Maud
Golinski, Marie-Laure
Balayé, Pierre
Prost-Squarcioni, Catherine
Houivet, Estelle
Calbo, Sé Bastien
Labeille, Bruno
Picard-Dahan, Catherine
Konstantinou, Maria Polina
Chaby, Guillaume
Richard, Marie-Aleth
Bouaziz, Jean-David
Duvert-Lehembre, Sophie
Delaporte, Emmanuel
Bernard, Philippe
Caux, Frédéric
Alexandre, Marina
Ingen-Housz-Oro, Saskia
Vabres, Pierre
Quéreux, Gaelle
Dupuy, Alain
Debarbieux, Sebastien
Avenel-Audran, Martine
d'Incan, Michel
Bedane, Christophe
Beneton, Nathalie
Jullien, Denis
Dupin, Nicolas
Misery, Laurent
Machet, Laurent
Beylot-Barry, Marie
Dereure, Olivier
Sassolas, Bruno
Bénichou, Jacques
Joly, Pascal
Hebert, Vivien
Calbo, Sébastien

May 2020

International audienceImportance: Rituximab and short-term corticosteroid therapy are the criterion ...

Rituximab for the Treatment of Relapses in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Miloslavsky, E. M.
Specks, U.
Merkel, P. A.
Seo, P.
Spiera, R.
Langford, C. A.
Hoffman, G. S.
Kallenberg, C. G. M.
Clair, E. W. St.
Tchao, N. K.
Viviano, L.
Ding, L.
Ikle, D.
Villarreal, M.
Jepson, B.
Brunetta, P.
Allen, N. B.
Fervenza, F. C.
Geetha, D.
Keogh, K.
Kissin, E. Y.
Monach, P. A.
Peikert, T.
Stegeman, C.
Ytterberg, S. R.
Stone, J. H.

November 2014

Objective. Disease relapses are frequent in anti-neutrophil cytoplasmic antibody-associated vasculit...

Rituximab Treatment for Relapsing Minimal Change Disease and Focal Segmental Glomerulosclerosis: A Systematic Review

Kronbichler, Andreas
Kerschbaum, Julia
Fernandez-Fresnedo, Gema
Hoxha, Elion
Kurschat, Christine E.
Busch, Martin
Bruchfeld, Annette
Mayer, Gert
Rudnicki, Michael

January 2014

Background: Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) remain a ther...

Risk of disease relapse following rituximab for patients with glucocorticoid and without glucocorticoid maintenance therapy at last follow-up or relapse.

Abstract

Extracted data

Risk of disease relapse following rituximab for patients with glucocorticoid and without glucocorticoid maintenance therapy at last follow-up or relapse.

Abstract

Extracted data

Topics

Related items

Topics

Related items